Clinical Trial Update: Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on a recombinant TNF-α receptor fusion protein for axial spondyloarthritis shows completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Spondyloarthritis

Drugs mentioned

• Recombinant human TNF-α receptor II IgG Fc fusion protein (Etanercept-origin or similar TNF receptor fusion protein)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Spondyloarthritis | Phase 4 | Status: COMPLETED